UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): March 30, 2017
Protea Biosciences Group, Inc.
(Exact Name of Registrant as Specified in Charter)
| Delaware | 000-51474 | 20-2903252 |
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
1311 Pineview Drive,
Suite 501
Morgantown, West Virginia 26505
(Address of Principal Executive Offices)
| Registrant’s telephone number, including area code: | (304) 292-2226 |
(Former Name of Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01 | Other Events. |
On March 2, 2017, Protea Biosciences Group, Inc., (the “Company”) filed with the Securities and Exchange Commission a definitive schedule 14A consent solicitation statement (the “Consent Solicitation”) and thereafter mailed the Consent Solicitation to all Company stockholders as of February 21, 2017 (the “Record Date”). Under the Consent Solicitation, as filed with the Securities and Exchange Commission, the Company expressly reversed the right, as determined in its sole discretion, to extend the deadline to receive written consents from Company shareholders, as of the Record Date.
On March 30, 2017 the Company’s board of directors approved the Company’s decision to exercise such discretionary right by extending the deadline to receive written consents under the Consent Solicitation from the original date of March 30, 2017 to the revised date of April 28, 2017.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Date: April 4, 2017 | PROTEA BIOSCIENCES GROUP, INC. | |
| By: | /s/ Stephen Turner | |
| Stephen Turner | ||
| Chief Executive Officer | ||